Autres langues Incyte Corporation

Actions

INCY

US45337C1027

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 05/10/2026			Varia. 5j.	Varia. 1 janv.
114,13 ^USD	-1,01%		-8,56%	+15,55%

05/10	Incyte Corporation : Stifel Nicolaus réitère son opinion positive sur le titre	ZM
02/10	Le S&P 500 en léger repli hebdomadaire, pénalisé par la santé et les services financiers	MT

Autres langues

02/10	S&P 500 Posts Slight Weekly Drop as Health Care, Financials Weigh
29/09	Pharma sector doubles down on AI to slash costs, timelines
28/09	Incyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDA
26/09	Mirum Pharmaceuticals, Inc. and Incyte Announce U.S. FDA Approval of Atebrioz for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
25/09	US FDA approves Mirum's drug for rare bone disorder
22/09	Die Daten von Incyte auf dem Kongress der Europäischen Akademie für Dermatologie und Venerologie (EADV) unterstreichen die Breite des Incyte-Portfolios im Bereich Entzündungen und Autoimmunerkrankungen
22/09	Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says
22/09	Incyte Announces Data Presentations At European Academy of Dermatology and Venereology Congress
22/09	Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
21/09	Pharma sector doubles down on AI to slash costs, timelines
21/09	Incyte Expands Skin Diseases Treatment Partnership in Australia
17/09	Incyte Insider Sold Shares Worth $2,797,629, According to a Recent SEC Filing
16/09	Pharma sector doubles down on AI to slash costs, timelines
10/09	Incyte Announces Funding of MINJUVI (Tafasitamab) for Relapsed or Refractory Follicular Lymphoma Through Ontario's FAST Program
10/09	Incyte Says Follicular Lymphoma Treatment Minjuvi Being Funded in Ontario Via FAST Program
01/09	Incyte to Present at Upcoming Investor Conferences
31/08	Incyte Corporation Enters Agreement with U.S. Centers for Medicare & Medicaid Services
28/08	US FDA approves Takeda, Protagonist's drug for rare blood cancer
28/08	Incyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil
20/08	Pharma sector doubles down on AI amid hopes of slashing costs, timelines
19/08	US FDA approves Regeneron's rare bone disorder drug
18/08	Global Vitiligo Foundation Applauds Incyte's 'Moments of Clarity' Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness
14/08	Incyte Insider Sold Shares Worth $1,296,792, According to a Recent SEC Filing
07/08	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/08	Incyte Insider Sold Shares Worth $273,646, According to a Recent SEC Filing